Engineered nanocarriers for targeted lung cancer therapy: mechanistic innovations and recent clinical progress
Heayyean Lee , Khadijah Sajid , Jeehoo Lee
Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) : 1002339
Lung cancer remains the leading cause of cancer mortality worldwide, with progress limited by tumor heterogeneity, drug resistance, and conventional therapy limitations. Nanotechnology-enabled drug delivery offers a transformative approach, enabling the precise engineering of nanocarriers for selective targeting, controlled release, and reduced toxicity. Recent innovations include inhalable systems that achieve localized pulmonary deposition, stimuli-responsive nanocarriers that release drugs in response to tumor microenvironment cues, and nano-immunotherapies that synergize with immune checkpoint blockade. Exosome-based vesicles further offer biomimetic advantages of low immunogenicity and natural tissue tropism. In parallel, theranostic platforms integrate treatment with imaging to enable real-time monitoring of drug delivery and tumor response. This review synthesizes mechanistic advances and translational developments in lung cancer nanomedicine, with emphasis on strategies that overcome biological barriers such as hypoxia, extracellular matrix density, and efflux pump activity. Clinical progress between 2020 and 2025 highlights next-generation antibody-drug conjugates, nanoparticle vaccines, and gene-loaded systems, several of which have reached regulatory approval or advanced trial stages. Together, these advances highlight the potential of nanocarriers to transform lung cancer therapy into more precise, personalized, and less toxic interventions.
lung cancer / nanomedicine / tumor microenvironment / inhalable nanomedicine / stimuli-responsive delivery / nano-immunotherapy / translational nanotechnology
| [1] |
Global cancer burden growing, amidst mounting need for services [Internet]. WHO; c2025 [cited 2024 Feb 1]. Available from: https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services |
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
Sarma K, |
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
Rosière R, Berghmans T, |
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
Ruiz A, Morais PC, de Azevedo RB, Lacava ZGM, Villanueva A, |
| [28] |
|
| [29] |
Moles E, Chang DW, Mansfeld FM, Duly A, Kimpton K, Logan A, |
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
Wang W, Fu F, Huang Z, Wang W, Chen M, Yue X, |
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
| [57] |
|
| [58] |
|
| [59] |
|
| [60] |
Yu Y, Li J, Song B, Ma Z, Zhang Y, Sun H, |
| [61] |
|
| [62] |
|
| [63] |
|
| [64] |
|
| [65] |
|
| [66] |
|
| [67] |
|
| [68] |
|
| [69] |
|
| [70] |
|
| [71] |
|
| [72] |
|
| [73] |
|
| [74] |
|
| [75] |
|
| [76] |
|
| [77] |
|
| [78] |
|
| [79] |
|
| [80] |
|
| [81] |
|
| [82] |
|
| [83] |
|
| [84] |
|
| [85] |
|
| [86] |
|
| [87] |
|
| [88] |
|
| [89] |
|
| [90] |
|
| [91] |
|
| [92] |
|
| [93] |
|
| [94] |
|
| [95] |
|
| [96] |
EnGeneIC launches groundbreaking new Australian trial for innovative cancer therapy, with international trial site in Singapore to follow [Internet]. [2025 Jul 10]. Available from: https://www.globenewswire.com/news-release/2025/05/13/3079706/0/en/EnGeneIC-launches-groundbreaking-new-Australian-trial-for-innovative-cancer-therapy-with-international-trial-site-in-Singapore-to-follow.html |
| [97] |
Deme D, Öven B, Göker E, Lang I, Brück P, Wenger M, |
| [98] |
|
| [99] |
Breaking Down the CONVERGE Study of NBTXR3 in Stage 3 Unresectable NSCLC [Internet]. MJH Life Sciences; c2025 [cited 2025 Jun 2]. Available from: https://www.curetoday.com/view/breaking-down-the-converge-study-of-nbtxr3-in-stage-3-unresectable-nsclc |
| [100] |
Targeted Oncology. Novel Radioenhancer JNJ-1900 Shows Potential across Cancers [Internet]. MJH Life Sciences; c2025 [cited 2025 Jul 10]. Available from: https://www.targetedonc.com/view/novel-radioenhancer-jnj-1900-shows-potential-across-cancers |
| [101] |
|
| [102] |
Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer [Internet]. [cited 2025 Jun 30]. Available from: https://www.genprex.com/genprex-expands-gene-therapy-oncology-pipeline-to-include-small-cell-lung-cancer/ |
| [103] |
|
| [104] |
|
| [105] |
|
| [106] |
|
| [107] |
|
| [108] |
|
| [109] |
|
| [110] |
|
| [111] |
|
| [112] |
|
/
| 〈 |
|
〉 |